RedHill Biopharma Announces Expected Timeline for DSMB Meeting and Provides Update on Enrollment in the RHB104 Phase III Study for Crohns Disease

The second independent Data and Safety Monitoring Board DSMB meeting of the RHB104 Phase III study for Crohns disease MAP US study is planned to be held in late July 2017 and will assess the safety and efficacy of RHB104 in the first 222 subjects who have ...